Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...
Stay updated with breaking news from Planned Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter...
09.02.2022 - -FC2 Prescription Business Entering 6th Year of Growth - -FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway- -Company Enters into Clinical Trial ...
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...